• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

More, More, More: Reducing Thrombosis in Acute Coronary Syndromes Beyond Dual Antiplatelet Therapy-Current Data and Future Directions.

作者信息

Spinthakis Nikolaos, Farag Mohamed, Rocca Bianca, Gorog Diana A

机构信息

Postgraduate Medical School, University of Hertfordshire, United Kingdom.

Pharmacology, Catholic University School of Medicine, Rome, Italy.

出版信息

J Am Heart Assoc. 2018 Jan 26;7(3):e007754. doi: 10.1161/JAHA.117.007754.

DOI:10.1161/JAHA.117.007754
PMID:29374045
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5850258/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3439/5850258/253ce756696d/JAH3-7-e007754-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3439/5850258/06dda88d4a77/JAH3-7-e007754-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3439/5850258/253ce756696d/JAH3-7-e007754-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3439/5850258/06dda88d4a77/JAH3-7-e007754-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3439/5850258/253ce756696d/JAH3-7-e007754-g002.jpg

相似文献

1
More, More, More: Reducing Thrombosis in Acute Coronary Syndromes Beyond Dual Antiplatelet Therapy-Current Data and Future Directions.更多，更多，更多：超越双联抗血小板治疗降低急性冠状动脉综合征中的血栓形成——当前数据与未来方向
J Am Heart Assoc. 2018 Jan 26;7(3):e007754. doi: 10.1161/JAHA.117.007754.
2
Is there a Role for Oral Triple Therapy in Patients with Acute Coronary Syndromes Without Atrial Fibrillation?急性冠状动脉综合征无房颤患者口服三联疗法的作用如何？
Curr Vasc Pharmacol. 2018;16(5):427-436. doi: 10.2174/1570161116666180117105339.
3
Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 Update.经皮冠状动脉介入治疗的口服抗凝治疗心房颤动患者的抗血栓治疗：北美视角-2018 年更新。
Circulation. 2018 Jul 31;138(5):527-536. doi: 10.1161/CIRCULATIONAHA.118.034722.
4
Novel Antiplatelet Agents: The Current State and What Is Coming Down the Pike.新型抗血小板药物：现状与未来趋势
Prog Cardiovasc Dis. 2015 Nov-Dec;58(3):267-77. doi: 10.1016/j.pcad.2015.08.009. Epub 2015 Aug 13.
5
Dual Anticoagulant and Antiplatelet Therapy for Coronary Artery Disease and Peripheral Artery Disease Patients.冠状动脉疾病和外周动脉疾病患者的双重抗凝和抗血小板治疗
Arterioscler Thromb Vasc Biol. 2018 Apr;38(4):726-732. doi: 10.1161/ATVBAHA.117.310048. Epub 2018 Feb 15.
6
New directions in antiplatelet therapy.抗血小板治疗的新方向。
Circ Cardiovasc Interv. 2012 Jun;5(3):433-45. doi: 10.1161/CIRCINTERVENTIONS.111.966176.
7
Contemporary Antithrombotic Treatment in Patients with Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: Rationale and Design of the Greek AntiPlatElet Atrial Fibrillation (GRAPE-AF) Registry.经皮冠状动脉介入治疗的非瓣膜性心房颤动患者的当代抗栓治疗：希腊抗血小板心房颤动（GRAPE-AF）注册研究的原理和设计。
Cardiovasc Drugs Ther. 2018 Apr;32(2):191-196. doi: 10.1007/s10557-018-6789-7.
8
Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.倡导使用 P2Y12 受体抑制剂的心血管精准医学。
Eur Heart J Cardiovasc Pharmacother. 2017 Oct 1;3(4):221-234. doi: 10.1093/ehjcvp/pvw044.
9
Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS.急性冠状动脉综合征或经皮冠状动脉介入治疗后早期和晚期心房颤动患者抗栓治疗的风险/获益权衡：来自 AUGUSTUS 的见解。
Circulation. 2020 May 19;141(20):1618-1627. doi: 10.1161/CIRCULATIONAHA.120.046534. Epub 2020 Mar 29.
10
Atrial fibrillation, bleeding, and coronary intervention: current recommendations.心房颤动、出血与冠状动脉介入治疗：当前推荐意见
Coron Artery Dis. 2017 Dec;28(8):702-709. doi: 10.1097/MCA.0000000000000549.

引用本文的文献

1
Left main coronary artery thrombus after cannabis consumption: a case report.吸食大麻后左冠状动脉主干血栓形成：一例报告
Eur Heart J Case Rep. 2021 Jun 14;5(6):ytab179. doi: 10.1093/ehjcr/ytab179. eCollection 2021 Jun.
2
Recurrent Stent Thrombosis: An Interventionalist's Nightmare.复发性支架内血栓形成：介入医生的噩梦。
J Am Heart Assoc. 2021 May 4;10(9):e020728. doi: 10.1161/JAHA.121.020728. Epub 2021 Apr 17.
3
Precision Treatment in ACS-Role of Assessing Fibrinolysis.急性冠状动脉综合征中的精准治疗——评估纤维蛋白溶解的作用

本文引用的文献

1
Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT.在接受新一代药物洗脱支架治疗的急性冠脉综合征患者中，氯吡格雷或替格瑞洛：CHANGE DAPT。
EuroIntervention. 2017 Nov 20;13(10):1168-1176. doi: 10.4244/EIJ-D-17-00634.
2
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.在急性冠脉综合征（GEMINI-ACS-1）中，与低剂量利伐沙班加 P2Y12 抑制相比，加用阿司匹林导致临床显著出血：一项双盲、多中心、随机试验。
Lancet. 2017 May 6;389(10081):1799-1808. doi: 10.1016/S0140-6736(17)30751-1. Epub 2017 Mar 18.
3
J Clin Med. 2021 Mar 1;10(5):929. doi: 10.3390/jcm10050929.
4
Long term efficacy and safety of rivaroxaban plus cilostazol in the treatment of critical ischemia of the lower limbs in a frail, elderly patient with non valvular atrial fibrillation.利伐沙班联合西洛他唑治疗老年体弱非瓣膜性心房颤动患者下肢严重缺血的长期疗效及安全性
J Pharm Health Care Sci. 2020 Aug 3;6:17. doi: 10.1186/s40780-020-00173-9. eCollection 2020.
5
Rationale and design of "Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)" study : A randomised trial modulating endogenous fibrinolysis in patients with acute coronary syndrome.“Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)”研究的原理和设计：急性冠脉综合征患者内源性纤溶调节的随机试验
J Thromb Thrombolysis. 2020 Feb;49(2):192-198. doi: 10.1007/s11239-019-02014-5.
6
TxA Receptor-Based Vaccination: A Novel Potential Therapeutic Approach to Limit Thrombosis.基于血栓素A受体的疫苗接种：一种限制血栓形成的新型潜在治疗方法。
J Am Heart Assoc. 2018 Jun 23;7(13):e009861. doi: 10.1161/JAHA.118.009861.
7
To Have and Have Not: Intrinsic Platelet Hyperreactivity?有与没有：血小板内在高反应性？
J Am Heart Assoc. 2018 Mar 3;7(5):e008750. doi: 10.1161/JAHA.118.008750.
Tailoring duration of DAPT with risk scores.
根据风险评分调整双联抗血小板治疗的持续时间。
Lancet. 2017 Mar 11;389(10073):987-989. doi: 10.1016/S0140-6736(17)30591-3.
4
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.经支架植入和随后双联抗血小板治疗（PRECISE-DAPT）的患者预测出血并发症的预测评分的推导和验证：来自临床试验的个体患者数据集的汇总分析。
Lancet. 2017 Mar 11;389(10073):1025-1034. doi: 10.1016/S0140-6736(17)30397-5.
5
Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease.替卡格雷与氯吡格雷在有症状外周动脉疾病中的比较。
N Engl J Med. 2017 Jan 5;376(1):32-40. doi: 10.1056/NEJMoa1611688. Epub 2016 Nov 13.
6
A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease.对阿司匹林用于缺血性心脏病患者二级预防的批判性重新评估。
Am Heart J. 2016 Nov;181:92-100. doi: 10.1016/j.ahj.2016.08.008. Epub 2016 Aug 30.
7
The clinical outcomes of triple antiplatelet therapy versus dual antiplatelet therapy for high-risk patients after coronary stent implantation: a meta-analysis of 11 clinical trials and 9,553 patients.冠状动脉支架植入术后高危患者三联抗血小板治疗与双联抗血小板治疗的临床结局：11项临床试验和9553例患者的荟萃分析
Drug Des Devel Ther. 2016 Oct 20;10:3435-3448. doi: 10.2147/DDDT.S119616. eCollection 2016.
8
Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.替格瑞洛与阿司匹林治疗急性卒中或短暂性脑缺血发作的比较
N Engl J Med. 2016 Oct 6;375(14):1394-1395. doi: 10.1056/NEJMc1610106.
9
Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI.复杂 PCI 后双联抗血小板治疗的疗效和安全性。
J Am Coll Cardiol. 2016 Oct 25;68(17):1851-1864. doi: 10.1016/j.jacc.2016.07.760. Epub 2016 Aug 29.
10
Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial.血小板功能监测以调整急性冠状动脉综合征支架置入老年患者的抗血小板治疗（南极洲研究）：一项开放标签、盲终点、随机对照优势试验
Lancet. 2016 Oct 22;388(10055):2015-2022. doi: 10.1016/S0140-6736(16)31323-X. Epub 2016 Aug 28.